Skip to main content
Clinical Trials/JPRN-jRCT2080221094
JPRN-jRCT2080221094
Unknown
Phase 3

A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler 0.4 mg and Salbutamol pMDI 200mcg - a Single Blind, Single Dose, Randomized, Crossover, Phase 3 Study in Japanese Adult Asthma Patients

AstraZeneca0 sitesMay 12, 2010
ConditionsAsthma

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Asthma
Sponsor
AstraZeneca
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2010
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • On ICS for at least 3 months from Visit 2 and with a prescribed constant dose during the 4 weeks prior to Visit 2
  • \- FEV1 of at least 50 % of predicted normal value pre\-bronchodilator
  • \- Reversible airway obstruction according to reversibility test performed at Visit 2, defined as an increase in FEV1 12% or more relative baseline at 15\-30 minutes after inhalation of in total 400mcg salbutamol

Exclusion Criteria

  • \- Treatment with oral, parenteral or rectal GCS within 4 weeks or depot parenteral GCS within 3 months prior to Visit 2\.
  • \- Change in prescribed asthma medication due to exacerbation of asthma within 4 weeks prior to Visit 2 or being hospitalized due to exacerbation of asthma within 8 weeks prior to Visit 2\.

Outcomes

Primary Outcomes

Not specified

Similar Trials